Elite Pharmaceuticals Inc (ELTP)

[Couch]

WHY JERRY TREPPEL WAS BROUGHT IN AS CEO
Elite now has the Eli 216 patent...and brought Jerry Treppel in to help with the financing problems and naked shorting difficulties Elite has historically been faced with....Thanks for this piece of info btw Lasers......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74972868

And I've posted my thoughts on what the founder Atul Mehta had in mind for the company..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77645055
This financial windfall for the company will be forthcoming......Elite doesn't need to garner enough funds to get through Phase III FDA trials immediately. That is good news for the investors right now. Elite can do BE studies and market products that will not require Phase III FDA trials and show Big Pharma that it is able to produce and manufacture what is says it can. However, when Elite is able to begin Phase III trials on Eli 216 this will be one of the watershed moments for Elite......and a signal to Big Pharma that Elite's abuse resistant technology will be one of the products used in the Gold Standard package relating to Pain Management and curtailing Opioid Abuse!

Having said this......as mentioned, Elite will need the funding to keep themselves afloat through this coming year.....and continue to contend with the corrupt MM's and Naked shorters.........Again, why the company brought in Jerry Treppel to begin with. They needed an expert in capital financing!!! I think they have the right man for the job to say the least.
http://www.globenewswire.com/newsroom/news.html?d=257381

Mr. Treppel has over 25 years experience in healthcare equity research, investment banking, and portfolio management. He was General Partner of Wheaten HealthCare Partners LP and Principal of Wheaten Capital Management LLC, a long/short equity healthcare fund. Mr. Treppel founded Wheaten with a strategy of exploiting market inefficiencies in small- and mid-cap companies, which are largely underfollowed by Wall Street. The fund focused on diverse subsectors of healthcare, including pharmaceuticals, generic drugs, drug delivery, biotechnology, medical technology, life science tools, pharmaceutical services, managed care and healthcare facilities. Prior to Wheaten, he was a Managing Director, Equity Securities, at Banc America Securities where he covered approximately 25 companies in the Specialty Pharmaceuticals industry.

From the CC:
"My vision is to create a line of abuse resistant opioid products using our patented technology. Push comes to shove, that's where the value -- the true large value of the Company is, is in the creation of that line of abuse resistant products. Nobody in management is working to see this Company grow by million-dollar increments.

We are going for the doubles, the triples, and the home runs. And we think we can do that.

If you look at the abuse resistant market and you look at some of the problems that other companies have had in manufacturing their products on a consistent basis, we think one of the big advantages that we have is that we have a system that can be consistently manufactured over and over again with many different products."

And....
"I mean, that's why we are excited about it. It's different. Quite frankly, it's much more straightforward, and it uses the pharmacologic approach, which clearly the FDA likes the best, because it's understandable in terms of the science. Okay?"